Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study

被引：0

作者：

Kumar, S. K. ^{[1
]}

Moreau, P. ^{[2
]}

Bahlis, N. ^{[3
]}

Facon, T. ^{[4
]}

Plesner, T. ^{[5
,6
]}

Orlowski, R. Z. ^{[7
]}

Basu, S. ^{[8
,9
]}

Nahi, H. ^{[10
]}

Hulin, C. ^{[11
]}

Quach, H. ^{[12
]}

Goldschmidt, H. ^{[13
,14
]}

O'Dwyer, M. ^{[15
]}

Perrot, A. ^{[16
]}

Venner, C. P. ^{[17
,18
]}

Weisel, K. ^{[19
]}

Raje, N. ^{[20
]}

Tiab, M. ^{[21
]}

Macro, M. ^{[22
]}

Frenzel, L. ^{[23
]}

Leleu, X. ^{[24
]}

Wang, G. ^{[25
]}

Krevvata, M. ^{[25
]}

Carson, R. ^{[25
]}

Borgsten, F. ^{[26
]}

Usmani, S. Z. ^{[27
]}

机构：

[1] Mayo Clin Rochester, Dept Hematol, Rochester, MN USA

[2] Univ Hosp Hotel Dieu, Hematol Dept, Nantes, France

[3] Univ Calgary, Arnie Charbonneau Canc Res Inst, Calgary, AB, Canada

[4] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[5] Vejle Hosp, Vejle, Denmark

[6] Univ Southern Denmark, Vejle, Denmark

[7] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[8] Royal Wolverhampton NHS Trust, Wolverhampton, England

[9] Wolverhampton Univ, CRN West Midlands, NIHR, Wolverhampton, England

[10] Karolinska Inst, Karolinska Univ Hosp Huddinge, Div Hematol, Dept Med, Stockholm, Sweden

[11] Univ Hosp, Dept Hematol, Hop Haut Leveque, Pessac, France

[12] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia

[13] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany

[14] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[15] NUI, Dept Med Haematol, Galway, Ireland

[16] Univ Toulouse, CHU Toulouse, Serv Hematol, IUCT O,UPS, Toulouse, France

[17] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[18] BC Canc, Vancouver Ctr Grp, Vancouver, BC, Canada

[19] Univ Med Ctr Hamburg Eppendorf, Sect Pneumol, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[20] Massachusetts Gen Hosp, Canc Ctr, Ctr Multiple Myeloma, Boston, MA 02114 USA

[21] CHD Vendee, La Roche Sur Yon, France

[22] Ctr Hosp Univ CHU Caen, Caen, France

[23] Hop Necker Enfants Malad, Paris, France

[24] CHU Poitiers, Hop Miletrie, Poitiers, France

[25] Janssen Res & Dev LLC, Spring House, PA USA

[26] Janssen Res & Dev LLC, Raritan, NJ USA

[27] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P342

引用

页码：183 / 184

页数：2

共 50 条

[21] Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)
Kaufman, Jonathan L.
Usmani, Saad Z.
San-Miguel, Jesus
Bahlis, Nizar
White, Darrell J.
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Krevvata, Maria
Pei, Huiling
Ukropec, Jon
Renaud, Thomas
Trivedi, Sonali
Kobos, Rachel
Dimopoulos, Meletios A.
BLOOD, 2019, 134
[22] Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose
Usmani, Saad Z.
Kumar, Shaji
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar J.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael E.
Perrot, Aurore
Venner, Chris P.
Weisel, Katja
Mace, Joseph R.
Raje, Noopur S.
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Van Rampelbergh, Rian
Tromp, Brenda
Delioukina, Maria
Facon, Thierry
BLOOD, 2021, 138
[23] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
Takamatsu, Hiroyuki
Iida, Shinsuke
Shibayama, Hirohiko
Shibayama, Kazuhiro
Yamazaki, Hiroshi
Suzuki, Kenshi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 692 - 701
[24] Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study
Hiroyuki Takamatsu
Shinsuke Iida
Hirohiko Shibayama
Kazuhiro Shibayama
Hiroshi Yamazaki
Kenshi Suzuki
International Journal of Hematology, 2020, 111 : 692 - 701
[25] Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Facon, Thierry
Venner, Christopher P.
Bahlis, Nizar J.
Offner, Fritz
White, Darrell J.
Karlin, Lionel
Benboubker, Lotfi
Rigaudeau, Sophie
Rodon, Philippe
Voog, Eric
Yoon, Sung-Soo
Suzuki, Kenshi
Shibayama, Hirohiko
Zhang, Xiaoquan
Twumasi-Ankrah, Philip
Yung, Godwin
Rifkin, Robert M.
Moreau, Philippe
Lonial, Sagar
Kumar, Shaji K.
Richardson, Paul G.
Rajkumar, S. Vincent
BLOOD, 2021, 137 (26) : 3616 - 3628
[26] Overall survival and progression-free survival by treatment duration with Daratumumab plus Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study
Moreau, Philippe
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher
Weisel, Katja
Mace, Joseph R.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Tromp, Brenda
Delioukina, Maria
Usmani, Saad Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S1 - S1
[27] Daratumumab plus Lenalidomide/ dexamethasone in transplant-neligible patients with newly diagnosed multiple myeloma: MAIA update
Basu, Supratik
Kumar, Shaji K.
Moreau, Philippe
Bahlis, Nizar
Facon, Thierry
Plesner, Torben
Orlowski, Robert Z.
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Krevvata, Maria
Borgsten, Fredrik
Usmani, Saad Z.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 17 - 18
[28] A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)
O'Donnell, Elizabeth K.
Suman, Vera Jean
Geyer, Susan M.
Nadeem, Omar
Dinner, Shira
Yee, Andrew J.
Laubach, Jacob P.
Mo, Clifton C.
Tuchman, Sascha A.
Donadio, Kristen
Sinclair, Sarah
Raje, Noopur S.
Richardson, Paul G.
BLOOD, 2021, 138
[29] Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
Dimopoulos, Meletios A.
San-Miguel, Jesus
Belch, Andrew
White, Darrell
Benboubker, Lotfi
Cook, Gordon
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe
Kaufman, Jonathan L.
Sutherland, Heather J.
Lalancette, Marc
Magen, Hila
Iida, Shinsuke
Kim, Jin Seok
Prince, H. Miles
Cochrane, Tara
Oriol, Albert
Bahlis, Nizar J.
Chari, Ajai
O'Rourke, Lisa
Wu, Kaida
Schecter, Jordan M.
Casneuf, Tineke
Chiu, Christopher
Soong, David
Sasser, A. Kate
Khokhar, Nushmia Z.
Avet-Loiseau, Herve
Usmani, Saad Z.
HAEMATOLOGICA, 2018, 103 (12) : 2088 - 2096
[30] Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
Perrot, Aurore
Facon, Thierry
Plesner, Torben
Usmani, Saad
Kumar, Shaji K.
Bahlis, Nizar Jacques
Hulin, Cyrille
Orlowski, Robert Z.
Nahi, Hareth
Mollee, Peter
Ramasamy, Karthik
Roussel, Murielle
Jaccard, Arnaud
Delforge, Michel
Karlin, Lionel
Arnulf, Bertrand
Chari, Ajai
Pei, Huiling
Gupta, Niodita
Kaila, Shuchita
Matt, Kathryn
Gries, Katharine S.
Carson, Robin
Borgsten, Fredrik
Weisel, Katja
BLOOD, 2022, 140 : 1142 - 1145

← 1 2 3 4 5 →